Germany Antibody Drug Conjugates Market Size & Outlook
Germany antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Germany antibody drug conjugates market highlights
- The Germany antibody drug conjugates market generated a revenue of USD 247.0 million in 2021 and is expected to reach USD 1,205.6 million by 2030.
- The Germany market is expected to grow at a CAGR of 19.3% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 247.0 million |
| Market revenue in 2030 | USD 1,205.6 million |
| Growth rate | 19.3% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Germany accounted for 4.3% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 758.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 65.95% in 2021. Horizon Databook has segmented the Germany antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Owing to factors such as advanced healthcare infrastructure and increased research on ADCs, Germany is expected to be one of the large revenue-generating markets for ADCs in Europe. Furthermore, several German pharmaceutical manufacturers are trying to enter the ADC market by investing in R&D.
For instance, Heidelberg Pharma and Tubulis have new ADC treatments in clinical & preclinical development. In July 2021, USD 12.3 million was raised by Tubulis, a German biotech company, for advancing research on ADCs and to particularly build on the research that identified linker chemistry to be more stable than the technology used in ADCs such as Seagen’s (previously Seattle Genetics) Adcetris.
However, high cost of the therapies is expected to impact market growth in the country. For instance, the annual therapy cost for Besponsa was USD 459,726 in 2017 in Germany. Health insurers in Germany are demanding stricter pharmaceutical cost-containment policies as spending on prescription drugs is increasing.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany antibody drug conjugates market size, by application, 2018-2030 (US$M)
Germany Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
